| Tumour angiogenesis regulation by the miR-200 family CV Pecot, R Rupaimoole, D Yang, R Akbani, C Ivan, C Lu, S Wu, HD Han, ... Nature communications 4 (1), 2427, 2013 | 435 | 2013 |
| Hematogenous metastasis of ovarian cancer: rethinking mode of spread S Pradeep, SW Kim, SY Wu, M Nishimura, P Chaluvally-Raghavan, ... Cancer cell 26 (1), 77-91, 2014 | 338 | 2014 |
| Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer EJ Faivre, KF McDaniel, DH Albert, SR Mantena, JP Plotnik, D Wilcox, ... Nature 578 (7794), 306-310, 2020 | 294 | 2020 |
| Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma YNV Gopal, H Rizos, G Chen, W Deng, DT Frederick, ZA Cooper, ... Cancer research 74 (23), 7037-7047, 2014 | 191 | 2014 |
| A switch in the source of ATP production and a loss in capacity to perform glycolysis are hallmarks of hepatocyte failure in advance liver disease T Nishikawa, N Bellance, A Damm, H Bing, Z Zhu, K Handa, MI Yovchev, ... Journal of hepatology 60 (6), 1203-1211, 2014 | 134 | 2014 |
| 2′-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity SY Wu, X Yang, KM Gharpure, H Hatakeyama, M Egli, MH McGuire, ... Nature communications 5 (1), 3459, 2014 | 128 | 2014 |
| Cupid: simultaneous reconstruction of microRNA-target and ceRNA networks HS Chiu, D Llobet-Navas, X Yang, WJ Chung, A Ambesi-Impiombato, ... Genome research 25 (2), 257-267, 2015 | 106 | 2015 |
| Adrenergic stimulation of DUSP1 impairs chemotherapy response in ovarian cancer Y Kang, AS Nagaraja, GN Armaiz-Pena, PL Dorniak, W Hu, ... Clinical Cancer Research 22 (7), 1713-1724, 2016 | 91 | 2016 |
| Sustained adrenergic signaling promotes intratumoral innervation through BDNF induction JK Allen, GN Armaiz-Pena, AS Nagaraja, NC Sadaoui, T Ortiz, R Dood, ... Cancer research 78 (12), 3233-3242, 2018 | 82 | 2018 |
| Notch3 pathway alterations in ovarian cancer W Hu, T Liu, C Ivan, Y Sun, J Huang, LS Mangala, T Miyake, HJ Dalton, ... Cancer research 74 (12), 3282-3293, 2014 | 76 | 2014 |
| Network motifs in JNK signaling V Sehgal, PT Ram Genes & cancer 4 (9-10), 409-413, 2013 | 76 | 2013 |
| Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer Y Wen, WS Graybill, RA Previs, W Hu, C Ivan, LS Mangala, B Zand, ... Clinical Cancer Research 21 (2), 448-459, 2015 | 69 | 2015 |
| Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer EG Seviour, V Sehgal, Y Lu, Z Luo, T Moss, F Zhang, SM Hill, W Liu, ... Oncogene 35 (6), 691-701, 2016 | 62 | 2016 |
| Veliparib in combination with carboplatin and etoposide in patients with treatment-naïve extensive-stage small cell lung cancer: a phase 2 randomized study LA Byers, D Bentsion, S Gans, K Penkov, CH Son, A Sibille, ... Clinical Cancer Research 27 (14), 3884-3895, 2021 | 45 | 2021 |
| Targeting KRas-dependent tumour growth, circulating tumour cells and metastasis in vivo by clinically significant miR-193a-3p EG Seviour, V Sehgal, D Mishra, R Rupaimoole, C Rodriguez-Aguayo, ... Oncogene 36 (10), 1339-1350, 2017 | 45 | 2017 |
| Veliparib in combination with platinum-based chemotherapy for first-line treatment of advanced squamous cell lung cancer: a randomized, multicenter phase III study SS Ramalingam, S Novello, SZ Guclu, D Bentsion, Z Zvirbule, M Szilasi, ... Journal of Clinical Oncology 39 (32), 3633, 2021 | 33 | 2021 |
| Estimation of the rate and effect of new beneficial mutations in asexual populations W Zhang, V Sehgal, DM Dinh, RBR Azevedo, TF Cooper, R Azencott Theoretical population biology 81 (2), 168-178, 2012 | 26 | 2012 |
| Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study JS Weber, MS Carlino, A Khattak, T Meniawy, G Ansstas, MH Taylor, ... The Lancet 403 (10427), 632-644, 2024 | 24 | 2024 |
| Biologic effects of platelet-derived growth factor receptor α blockade in uterine cancer JW Roh, J Huang, W Hu, XY Yang, NB Jennings, V Sehgal, BH Sohn, ... Clinical Cancer Research 20 (10), 2740-2750, 2014 | 19 | 2014 |
| Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study EM Swisher, C Aghajanian, DM O'Malley, GF Fleming, SH Kaufmann, ... Gynecologic oncology 164 (2), 245-253, 2022 | 18 | 2022 |
